SNDX - Syndax Pharma announces new data for SNDX-5613 in trial for acute leukemias

Announcing its Q1 2021 financials, Syndax Pharmaceuticals (SNDX) updated the results of the company’s Phase 1/2 AUGMENT-101 trial of SNDX-5613 in patients with MLLr and NPM1c mutant relapsed/refractory (R/R) acute leukemias.The new data indicate that the two prior responders of the study have advanced to a complete response ((CR)) from complete response with incomplete platelet recovery ((CRp)).With the addition of new results, the number of patients with CR/CRh (CR with partial hematological recovery) has risen to seven (7/31) or 23%.Syndax also announced the completion of enrollment in the Phase 2 expansion portion of the Phase 1/2 trial of axatilimab, an anti-CSF-1R monoclonal antibody undergoing development for patients with chronic graft versus host disease ((cGVHD)).The updated results from 40 patients are likely later this year, the company said.In April, Syndax announced positive data from the AUGMENT-101 trial indicating a 48% of overall response rate among evaluable patients.Today, Syndax has beaten the Street forecasts with

For further details see:

Syndax Pharma announces new data for SNDX-5613 in trial for acute leukemias